3-FLUORO-7-(2,2,2-TRIFLUOROETHOXY)PHENOXATHIN-10,10-DIOXIDE

Name: 3-FLUORO-7-(2,2,2-TRIFLUOROETHOXY)PHENOXATHIN-10,10-DIOXIDE in Major Depressive Disorder
Creator: Floatz
License: https://terminal.floatz.ai/terms

Major Depressive Disorder

CeNeRx BioPharma Inc.Small moleculePhase 2Dormant

CCC

55/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 65/ 100

Competitive context

198 Active assets in the Major Depressive Disorder cohort.

Asset / Sponsor	Phase	Rating
Zelapar Corium Innovations, Inc.	Phase 4	BBB
Risperdal Johns Hopkins University	Phase 4	BBB
EDIVOXETINE Eli Lilly and Company	Phase 3	BBB
Opc-34712 Nova Scotia Health Authority	Phase 4	BBB
Vortioxetine Mayo Clinic	Phase 4	BBB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →